Genocea Biosciences Company Profile (NASDAQ:GNCA)

About Genocea Biosciences (NASDAQ:GNCA)

Genocea Biosciences logoGenocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes. It also has a pre-clinical immuno-oncology program focused on personalized cancer vaccines (GEN-009). The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual's tumor.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GNCA
  • CUSIP: N/A
  • Web:
  • Market Cap: $141.1 million
  • Outstanding Shares: 28,502,000
Average Prices:
  • 50 Day Moving Avg: $5.38
  • 200 Day Moving Avg: $5.41
  • 52 Week Range: $3.28 - $7.29
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.44
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.16 per share
  • Price / Book: 4.35
  • EBIDTA: ($51,980,000.00)
  • Return on Equity: -101.62%
  • Return on Assets: -71.11%
  • Debt-to-Equity Ratio: 0.37%
  • Current Ratio: 4.97%
  • Quick Ratio: 4.97%
  • Average Volume: 255,490 shs.
  • Beta: 2.24
  • Short Ratio: 18.88
Frequently Asked Questions for Genocea Biosciences (NASDAQ:GNCA)

What is Genocea Biosciences' stock symbol?

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

How were Genocea Biosciences' earnings last quarter?

Genocea Biosciences, Inc. (NASDAQ:GNCA) announced its earnings results on Thursday, May, 4th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.06. View Genocea Biosciences' Earnings History.

Where is Genocea Biosciences' stock going? Where will Genocea Biosciences' stock price be in 2017?

4 brokerages have issued 1-year target prices for Genocea Biosciences' shares. Their predictions range from $12.00 to $40.00. On average, they anticipate Genocea Biosciences' share price to reach $21.00 in the next twelve months. View Analyst Ratings for Genocea Biosciences.

What are analysts saying about Genocea Biosciences stock?

Here are some recent quotes from research analysts about Genocea Biosciences stock:

  • 1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (7/17/2017)
  • 2. Needham & Company LLC analysts commented, "Genocea announced positive results from its Phase 2b trial of GEN-003 in Herpes Simplex Type 2 (HSV2) in early Jan 2017. Given financial constraints, however, mgmt now plans to seek a collaborator prior to initiation of Phase 3 development. We believe this creates meaningful uncertainty for GEN-003 development timelines as well as the stock. Mgmt previously announced a shift in strategic focus from infectious disease to immuno-oncology. However, initial candidate from latter program is not expected to reach clinical development until YE17. We are downgrading to HOLD based on uncertainty around GEN-003 and lack of near-term milestones w/ immuno-oncology program. ATLAS platform holds substantial value and we believe stock remains attractive for long-term investors w/ horizon beyond 2017." (2/17/2017)

Who are some of Genocea Biosciences' key competitors?

Who are Genocea Biosciences' key executives?

Genocea Biosciences' management team includes the folowing people:

  • Katrine S. Bosley, Chairman of the Board
  • William D. Clark, President, Chief Executive Officer, Director
  • Jonathan M. Poole, Chief Financial Officer
  • John E. Bishop Ph.D., Executive Vice President - Pharmaceutical Sciences
  • Jessica Baker Flechtner Ph.D., Chief Scientific Officer
  • Seth V. Hetherington M.D., Chief Medical Officer
  • Eric S. Hoffman Ph.D., Chief Business Officer
  • Ronald Harold Wilfred Cooper, Director
  • George Siber M.D., Director
  • Kenneth M. Bate, Independent Director

How do I buy Genocea Biosciences stock?

Shares of Genocea Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genocea Biosciences' stock price today?

One share of Genocea Biosciences stock can currently be purchased for approximately $5.05.

MarketBeat Community Rating for Genocea Biosciences (NASDAQ GNCA)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  138 (Vote Outperform)
Underperform Votes:  47 (Vote Underperform)
Total Votes:  185
MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Genocea Biosciences (NASDAQ:GNCA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $21.00 (315.84% upside)

Analysts' Ratings History for Genocea Biosciences (NASDAQ:GNCA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/17/2017Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
1/23/2017FBR & CoReiterated RatingOutperformN/AView Rating Details
12/14/2016Cowen and CompanySet Price TargetBuy$40.00N/AView Rating Details
9/29/2016Piper Jaffray CompaniesLower Price TargetOverweight$9.00 -> $12.00N/AView Rating Details
4/1/2016Stifel NicolausBoost Price TargetBuy$11.00 -> $13.00N/AView Rating Details
(Data available from 7/22/2015 forward)


Earnings History for Genocea Biosciences (NASDAQ:GNCA)
Earnings by Quarter for Genocea Biosciences (NASDAQ:GNCA)
Earnings History by Quarter for Genocea Biosciences (NASDAQ GNCA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/20173/31/2017($0.54)($0.48)ViewListenView Earnings Details
2/16/2017Q416($0.45)($0.56)ViewN/AView Earnings Details
11/3/2016Q316($0.44)($0.45)ViewN/AView Earnings Details
8/4/2016Q216($0.44)($0.39)ViewN/AView Earnings Details
5/5/2016Q116($0.42)($0.35)$0.24 millionViewN/AView Earnings Details
2/11/2016Q415($0.40)($0.37)$0.22 millionViewListenView Earnings Details
11/5/2015Q315($0.43)($0.37)$0.21 millionViewListenView Earnings Details
8/6/2015Q215($0.51)($0.43)$0.12 millionViewN/AView Earnings Details
5/7/2015Q115($0.57)($0.64)$0.12 millionViewListenView Earnings Details
2/12/2015Q414($0.53)($0.66)$0.31 millionViewListenView Earnings Details
11/6/2014Q314($0.43)($0.53)ViewN/AView Earnings Details
8/6/2014Q2($0.42)($0.41)ViewN/AView Earnings Details
5/6/2014Q114($0.60)($0.76)$0.26 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Genocea Biosciences (NASDAQ:GNCA)
Current Year EPS Consensus Estimate: $-1.87 EPS
Next Year EPS Consensus Estimate: $-2.07 EPS


Dividend History for Genocea Biosciences (NASDAQ:GNCA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Genocea Biosciences (NASDAQ:GNCA)
Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 54.22%
Insider Trades by Quarter for Genocea Biosciences (NASDAQ:GNCA)
Institutional Ownership by Quarter for Genocea Biosciences (NASDAQ:GNCA)
Insider Trades by Quarter for Genocea Biosciences (NASDAQ:GNCA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/8/2016Eric S. HoffmanInsiderBuy7,000$3.49$24,430.00View SEC Filing  
11/7/2016Jonathan PooleCFOBuy7,000$3.34$23,380.00View SEC Filing  
11/7/2016William D. ClarkInsiderBuy2,800$3.49$9,772.00View SEC Filing  
5/9/2016Jonathan PooleCFOBuy4,000$3.88$15,520.00View SEC Filing  
12/16/2015William D ClarkCEOBuy3,800$6.45$24,510.00View SEC Filing  
9/1/2015Jessica Baker FlechtnerVPSell2,229$11.35$25,299.15View SEC Filing  
6/19/2015Polaris Venture Management Co.Major ShareholderSell30,004$13.04$391,252.16View SEC Filing  
6/17/2015Polaris Venture Management Co.Major ShareholderSell10,618$13.01$138,140.18View SEC Filing  
6/16/2015Polaris Venture Management Co.Major ShareholderSell46,000$13.24$609,040.00View SEC Filing  
6/1/2015Jessica Baker FlechtnerVPSell2,229$10.52$23,449.08View SEC Filing  
5/1/2015Jessica Baker FlechtnerVPSell2,229$10.21$22,758.09View SEC Filing  
4/1/2015Jessica Baker FlechtnerVPSell2,283$11.77$26,870.91View SEC Filing  
3/17/2015Stephen J HoffmanDirectorBuy700,000$8.25$5,775,000.00View SEC Filing  
2/2/2015Jessica Baker FlechtnerVPSell4,699$8.50$39,941.50View SEC Filing  
9/12/2014Jessica Baker FlechtnerVPSell6,435$12.00$77,220.00View SEC Filing  
9/11/2014Paul GiannascaVPSell4,071$11.84$48,200.64View SEC Filing  
9/10/2014Paul GiannascaVPSell834$12.35$10,299.90View SEC Filing  
9/9/2014Paul GiannascaVPSell2,455$12.43$30,515.65View SEC Filing  
9/8/2014Paul GiannascaVPSell2,970$12.80$38,016.00View SEC Filing  
8/29/2014Paul GiannascaVPSell6,760$12.50$84,500.00View SEC Filing  
8/14/2014Polaris Venture Management Co.Major ShareholderSell9,660$13.01$125,676.60View SEC Filing  
8/12/2014Polaris Venture Management Co.Major ShareholderSell63,794$13.28$847,184.32View SEC Filing  
2/10/2014Plc GlaxosmithklineInsiderBuy143,773$12.00$1,725,276.00View SEC Filing  
2/10/2014Polaris Venture Management Co.Major ShareholderBuy232,820$12.00$2,793,840.00View SEC Filing  
2/10/2014Stephen J HoffmanDirectorBuy250,931$12.00$3,011,172.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Genocea Biosciences (NASDAQ:GNCA)
Latest Headlines for Genocea Biosciences (NASDAQ:GNCA)
DateHeadline logoGenocea Biosciences, Inc. (NASDAQ:GNCA) Lowered to "Hold" at Zacks Investment Research - July 17 at 11:08 PM logoGenocea Biosciences, Inc. (GNCA) Expected to Post Earnings of -$0.46 Per Share - July 14 at 11:32 AM logoGenocea Biosciences, Inc. (GNCA) Given Average Rating of "Buy" by Brokerages - July 11 at 8:26 AM logoGenocea Added to Russell 3000® and Russell 2000® Indices - June 26 at 9:32 AM logo Brokerages Anticipate Genocea Biosciences, Inc. (GNCA) Will Announce Earnings of -$0.46 Per Share - June 20 at 8:16 AM logoGenocea Biosciences, Inc. (GNCA) Given Consensus Rating of "Buy" by Analysts - June 16 at 8:16 AM logoGenocea Biosciences Inc (GNCA) Lifted to Buy at Zacks Investment Research - June 6 at 11:02 PM logoGenocea Biosciences Inc (GNCA) Downgraded by Zacks Investment Research to Hold - June 5 at 11:16 PM logoGenocea: Investment Update On ~$6 Biotech 'Busted IPO ... - Seeking Alpha - June 1 at 3:28 AM logoGenocea Biosciences Inc (GNCA) Upgraded at Zacks Investment Research - May 31 at 11:24 PM logoGenocea Biosciences Inc (GNCA) Downgraded by Zacks Investment Research - May 31 at 12:02 AM logoGenocea Biosciences Inc (GNCA) Given Consensus Recommendation of "Buy" by Brokerages - May 22 at 7:56 AM logoGenocea Biosciences Inc (GNCA) Short Interest Update - May 16 at 7:20 AM logoGenocea Biosciences Inc (GNCA) Issues Earnings Results - May 8 at 4:40 PM logoGenocea Reports First Quarter 2017 Financial Results and Positive Clinical Developments on Lead Candidate GEN-003 in Genital Herpes - May 4 at 12:07 PM logoInvestor Network: Genocea Biosciences, Inc. to Host Earnings Call - May 4 at 12:07 PM logoGenocea Biosciences reports 1Q loss - May 4 at 9:29 AM logoZacks: Brokerages Expect Genocea Biosciences Inc (GNCA) Will Post Earnings of -$0.54 Per Share - May 2 at 12:06 AM logoGenocea Biosciences (GNCA) Earning Somewhat Critical Media Coverage, Analysis Shows - April 30 at 8:02 AM logoGenocea to Host First Quarter 2017 Financial Results Conference Call & Webcast on May 4, 2017 at 9 a.m. ET - April 27 at 8:05 AM logoSomewhat Positive Press Coverage Extremely Likely to Impact Genocea Biosciences (GNCA) Stock Price - April 26 at 8:44 AM logoGenocea Biosciences Inc (GNCA) Given Average Rating of "Buy" by Brokerages - April 25 at 11:05 AM logoGenocea Biosciences (GNCA) Receives Media Impact Score of -0.22 - April 20 at 8:53 AM logoGenocea Biosciences (GNCA) Receiving Very Favorable Media Coverage, AlphaOne Reports - April 15 at 8:58 AM logoGenocea Awarded World Vaccine Congress 2017 Industry Excellence Award for Best Therapeutic Vaccine for GEN-003 for Genital Herpes - April 11 at 12:15 PM logo Brokerages Anticipate Genocea Biosciences Inc (GNCA) Will Post Earnings of -$0.54 Per Share - April 10 at 8:30 PM logoGenocea Biosciences (GNCA) Presents At 16th Annual Needham Healthcare Conference - Slideshow - April 7 at 10:05 AM logoGenocea Biosciences Inc (GNCA) Given Consensus Rating of "Buy" by Brokerages - March 30 at 12:58 PM logoGenocea to Present at the 16th Annual Needham Healthcare Conference - March 29 at 11:07 AM logoGenocea Biosciences (GNCA) Jumps: Stock Moves 12% Higher - Nasdaq - March 9 at 5:55 PM logoGenocea Biosciences (GNCA) Presents At Cowen and Company 37th Annual Health Care Conference - March 8 at 6:17 PM logoGenocea Biosciences (GNCA) Appoints Howard Mayer M.D. to ... - - March 7 at 11:22 AM logoGENOCEA BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh - March 6 at 5:08 PM logoHoward Mayer, M.D., of Shire, Joins Genocea Biosciences’ Board of Directors - March 6 at 9:27 AM logoGenocea to Present at the Cowen and Company 37th Annual Health Care Conference - March 1 at 12:15 PM logoGENOCEA BIOSCIENCES, INC. Financials - February 23 at 5:29 PM logoGENOCEA BIOSCIENCES, INC. Files SEC form 10-K, Annual Report - February 18 at 12:23 PM logoGenocea Biosciences downgraded by Needham - February 17 at 4:04 PM logoQ4 2016 Genocea Biosciences Inc Earnings Release - Time Not Supplied - February 16 at 5:24 PM logoGenocea Reports Fourth Quarter and Year-End 2016 Financial Results - February 16 at 5:24 PM logoGENOCEA BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and - February 16 at 5:24 PM logoGenocea to Host Fourth Quarter and Year End 2016 Financial Results Conference Call & Webcast on February 16, 2017 - February 9 at 6:16 PM logoShould You Sell Genocea Biosciences (GNCA) Before Earnings? - Nasdaq - February 8 at 11:06 PM logoShould You Sell Genocea Biosciences (GNCA) Before Earnings? - February 7 at 6:45 PM logoGenocea Reports Positive 6-Month Results From GEN-003 Phase 2b Trial - January 5 at 6:25 PM logoGenocea Biosciences (GNCA) Announces Positive Interim Analysis of GEN-003 Phase 2b Clinical Trial - January 5 at 6:25 PM



Genocea Biosciences (GNCA) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by Staff